Before presuming the experts are worthless to you, please realize one thing. An amorphous solvate is a nightmare in disguise. So long as the trapped solvent is innocuous, there's no need to worry. What is cause for concern, however, is a change in crystalline structure upon standing or exposure to a certain temperature for prolonged conditions.
Any experienced drug development chemist will tell you that polymorphs can lead to trouble. If you manage to go to clinical trials with a polymorph, making it into Phase III, then have a batch of Phase III material become crystalline.... then my friend, you're screwed, and so is you clinical study, and so is your company. Why? Because you haven't characterized the crystalline form of the drug.
I designed drugs for 15 years (placed three into clinical trials) and I've seen this happen on more than one occasion. If there is any way to make a salt of your compound so the solvent is eliminated, I'd suggest going that route. If not, I'd suggest investing time into finding an energetically stable crystalline form to prevent the scenario I've just described.
What would be quite interesting is to see if a competing company can take your IP, develop a crystalline entity, and then patent the use of that particular crystal form. I've never heard of this happening, however there's always a first time for everything.
One more thing. If a competing company makes a prodrug of your compound and proves use of the prodrug is superior to delivery of the active form, you may also have something to worry about. You can claim prodrugs in your broad scope, however, unless you make the prodrugs you claim, I'd hate to be the one who has to argue the case in court.
A patent is not a patent until challenged in court. Until then, it's merely an approved application.
Good luck!